See also: Generic Coreg CR
Coreg is a brand name of carvedilol, approved by the FDA in the following formulation(s):
COREG (carvedilol - tablet; oral)
Manufacturer: SMITHKLINE BEECHAM
Approval date: September 14, 1995
Strength(s): 12.5MG [RLD][AB], 25MG [AB], 6.25MG [AB]
Manufacturer: SMITHKLINE BEECHAM
Approval date: May 29, 1997
Strength(s): 3.125MG [AB]
Has a generic version of Coreg been approved?
A generic version of Coreg has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Coreg and have been approved by the FDA:
carvedilol tablet; oral
Manufacturer: APOTEX INC
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: AUROBINDO PHARMA
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: BEXIMCO USA
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: CARACO
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: GLENMARK GENERICS
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: HIKMA
Approval date: September 7, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: LUPIN
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: MYLAN
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: PLIVA HRVATSKA DOO
Approval date: October 30, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: RANBAXY
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: SANDOZ
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: TARO
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: TEVA
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: WATSON LABS
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: WOCKHARDT
Approval date: December 22, 2009
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Manufacturer: ZYDUS PHARMS USA INC
Approval date: September 5, 2007
Strength(s): 12.5MG [AB], 25MG [AB], 3.125MG [AB], 6.25MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Method of treatment for decreasing mortality resulting from congestive heart failure
Patent RE40000
Issued: January 8, 2008
Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil Howard & Sponer; Gisbert & Strein; Klaus
Assignee(s): SB Pharmco Puerto Rico Inc.
A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.Patent expiration dates:
- June 7, 2015✓
- December 7, 2015✓
- June 7, 2015
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 23, 2010 - PEDIATRIC EXCLUSIVITY
See also...
- Coreg Consumer Information (Drugs.com)
- Coreg Consumer Information (Wolters Kluwer)
- Coreg Consumer Information (Cerner Multum)
- Coreg Advanced Consumer Information (Micromedex)
- Carvedilol Consumer Information (Wolters Kluwer)
- Carvedilol Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Carvedilol Consumer Information (Cerner Multum)
- Carvedilol Advanced Consumer Information (Micromedex)
- Carvedilol AHFS DI Monographs (ASHP)
No comments:
Post a Comment